What is the role of the MAYO score in diagnosing hypertrophic obstructive cardiomyopathy (HOCM)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

The MAYO score is not used for diagnosing hypertrophic obstructive cardiomyopathy (HOCM), but rather for risk stratification of patients already diagnosed with this condition. The MAYO score helps predict the risk of sudden cardiac death in HOCM patients, which guides decisions about preventive interventions such as implantable cardioverter-defibrillator (ICD) placement.

Key Components of the MAYO Score

The score incorporates several clinical variables including:

  • Age
  • Family history of sudden cardiac death
  • Unexplained syncope
  • Left ventricular outflow tract gradient
  • Maximum left ventricular wall thickness
  • Left atrial diameter
  • Presence of non-sustained ventricular tachycardia Each factor is assigned points, and the total score estimates the 5-year risk of sudden cardiac death. For example, a score of 6 or higher typically indicates high risk (>6% 5-year risk), which might warrant ICD implantation 1.

Diagnosis of HOCM

The actual diagnosis of HOCM relies on different criteria, primarily echocardiographic findings showing asymmetric septal hypertrophy with left ventricular wall thickness ≥15 mm (or ≥13 mm with family history), along with clinical symptoms, electrocardiographic changes, and sometimes genetic testing. Understanding this distinction is important for proper patient management, as misapplying the MAYO score for diagnostic purposes rather than risk assessment could lead to inappropriate clinical decisions.

Recent Guidelines and Recommendations

Recent studies, such as the one published in 2024 2, emphasize the importance of proper diagnosis and risk stratification in managing HOCM, highlighting the role of pharmacotherapy, septal reduction treatments, and management of sequelae like atrial fibrillation and malignant arrhythmias.

Clinical Implications

In clinical practice, the MAYO score should be used judiciously, considering the individual patient's risk factors and clinical presentation, to guide decisions about preventive interventions and management strategies, as supported by recent evidence 3, 4.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.